MedCity News’ Brandon Glenn discusses the opportunities a new progesterone drug could have for Ohio medical device company CerviLenz on this week’s edition of Health Journal on ONN.
CerviLenz’s device provides a means of accurately and inexpensively measuring a pregnant woman’s cervix. The new drug, Prochieve 8%, is a gel that was associated in a Phase 3 clinical trial with a 45 percent reduction in preterm births in pregnant women with a short cervix. It could be approved by the FDA for that indication by the end of the year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CerviLenz’s device, which is already on the market, can be used as a screening tool to identify candidates for the drug.
A short cervix is the best predictor of preterm birth risk.
“Looking for this problem and being able to do something about it is the biggest advance in obstetrics in 30 years,” said Dean Koch, CerviLenz’s CEO.
ONN broadcasts Health Journal featuring MedCity News throughout the week starting on Tuesdays.
